UBS Starts Abbvie (ABBV) at Neutral

January 11, 2013 12:46 PM EST
Get Alerts ABBV Hot Sheet
Price: $61.99 --0%

Rating Summary:
    10 Buy, 12 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade ABBV Now!
Join SI Premium – FREE
Earlier, UBS initiated coverage on Abbvie (NYSE: ABBV) with a Neutral rating and $36 price target.

The firm comments, "Our thesis is three-fold: (1) Humira should be durable but competition from oral therapies and generics for now will remain a concern for investors. (2) Earnings in 2013/2014 will be held down by ~$2.5-3B sales hit from its lipid and HIV franchises going generic. (3) The late stage pipeline doesn’t kick in until 2015-16 and it’s still unclear how big its most important asset, the HCV franchise, will be given how quickly market dynamics are changing."

EPS estimates are $3.08 for 2013 and $3.20 for 2014. 5 year CAGRs are 1% for revenues and 2% for EPS.

For an analyst ratings summary and ratings history on Abbvie click here. For more ratings news on Abbvie click here.

Shares of Abbvie closed at $34.00 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

New Coverage

Related Entities

UBS, Earnings

Add Your Comment